Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma

Next Previous
Trial Profile

A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tebentafusp (Primary)
  • Indications Uveal melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms IMCgp100-102
  • Sponsors Immunocore

    • Most Recent Events

    • 24 Oct 2023 Results exploring effects of ImmTAC-redirected T cell activation on macrophage reprogramming using baseline and on-treatment tumor biopsies from this trial in mUM HLA-A*02:01+ patients treated with tebentafusp ; used to quantify CD163+ and CD3+ cells by immunohistochemistry, and to measure gene expression presented at the 48th European Society for Medical Oncology Congress
    • 19 Apr 2023 Results of final analysis of OS of the Ph2 IMCgp100-102 study presented at the 114th Annual Meeting of the American Association for Cancer Research
    • 19 Apr 2023 Results of pooled analysis assessing the safety and efficacy from tebentafusp treated mUM patients with orbital lesions including intraocular lesions from IMCgp100-01 (n=19), IMCgp100-102 (n=146) and IMCgp100-202 (n=245) trials, presented at the 114th Annual Meeting of the American Association for Cancer Research.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top